165 related articles for article (PubMed ID: 22855181)
1. Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics.
Wan L; Li X; Shen H; Bai X
Clin Transl Oncol; 2013 Feb; 15(2):132-8. PubMed ID: 22855181
[TBL] [Abstract][Full Text] [Related]
2. [Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray].
Bai XY; Shen H
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1423-6. PubMed ID: 17062341
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
4. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
[TBL] [Abstract][Full Text] [Related]
5. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
6. EZH2 is a sensitive marker of malignancy in salivary gland tumors.
Hajósi-Kalcakosz S; Vincze E; Dezső K; Paku S; Rókusz A; Sápi Z; Tóth E; Nagy P
Diagn Pathol; 2015 Sep; 10():163. PubMed ID: 26377323
[TBL] [Abstract][Full Text] [Related]
7. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
8. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
Alford SH; Toy K; Merajver SD; Kleer CG
Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
10. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
11. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.
Geng J; Li X; Zhou Z; Wu CL; Dai M; Bai X
Cancer Lett; 2015 Apr; 359(2):275-87. PubMed ID: 25633838
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.
Hayashi A; Morikawa T; Kawai T; Kume H; Ishikawa S; Homma Y; Fukayama M
Virchows Arch; 2014 Apr; 464(4):463-71. PubMed ID: 24446035
[TBL] [Abstract][Full Text] [Related]
13. The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Meng X; Huang Z; Wang R; Jiao Y; Li H; Xu X; Feng R; Zhu K; Jiang S; Yan H; Yu J
Radiat Oncol; 2014 Aug; 9():188. PubMed ID: 25159232
[TBL] [Abstract][Full Text] [Related]
14. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis.
Wang CG; Ye YJ; Yuan J; Liu FF; Zhang H; Wang S
World J Gastroenterol; 2010 May; 16(19):2421-7. PubMed ID: 20480530
[TBL] [Abstract][Full Text] [Related]
15. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
Lv Y; Yuan C; Xiao X; Wang X; Ji X; Yu H; Wu Z; Zhang J
Oncol Rep; 2012 Jul; 28(1):147-54. PubMed ID: 22552406
[TBL] [Abstract][Full Text] [Related]
16. EZH2, a unique marker of malignancy in effusion cytology.
Jiang H; Gupta R; Somma J
Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
[TBL] [Abstract][Full Text] [Related]
17. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.
Wang H; Albadine R; Magheli A; Guzzo TJ; Ball MW; Hinz S; Schoenberg MP; Netto GJ; Gonzalgo ML
Urol Oncol; 2012; 30(4):428-33. PubMed ID: 21396836
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer.
Kim NY; Pyo JS
Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757
[TBL] [Abstract][Full Text] [Related]
19. EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma.
Xu ZQ; Zhang L; Gao BS; Wan YG; Zhang XH; Chen B; Wang YT; Sun N; Fu YW
Clin Transl Oncol; 2015 Jan; 17(1):41-9. PubMed ID: 24986100
[TBL] [Abstract][Full Text] [Related]
20. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
